Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Communications With Payors: US FDA Okays Info On Investigational Drugs

Executive Summary

Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.


Related Content

Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says
US FDA Extends Payor Communications Safe Harbor To Off-Label Uses
Off-Label Communications: US FDA Won't Impede Discussions With Payers, Gottlieb Says
What Does Rachel Sherman Think About Top FDA Regulatory Issues?
Off-Label Communications Bill Allowing Discussion Of Unapproved Drugs Advances
Observational Studies Should Get Safe Harbor For Preregistering Protocols – Humana
FDA's Promotional Reviews Decline, But Says It's Only Part Of Job
Off-Label Communications: Legislative Reform Efforts Struggle, But Continue
Off-Label Communication: When Does It Align With Approved Labeling?
US FDA Clarifies ‘Intended Use’ Policy For Approved Products





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts